San Diego—If approved, a therapy in development for primary biliary cholangitis might allow some patients with refractory disease to avoid liver transplant, thus eliminating one of the more costly interventions for the condition, according to new research presented at the 2022 Digestive Disease Week.
In earlier results from a phase 2 clinical study, the experimental agent seladelpar (CymaBay), a peroxisome proliferator–activated receptor-delta agonist, was associated